Senior figures from across industry, academia, investment and government met yesterday (Thursday 26 March 2026) at the House of Lords, for a roundtable hosted by The Lord Ranger of Northwood, to discuss the findings of a new report commissioned by Pioneer Group and The Crown Estate, and authored by Henham Strategy.
Join us at Hauxton House for the o2h ChaiTime — Discovery Club.
We are excited to introduce o2h ChaiTime — Discovery Club - an invite-only forum designed to bring together Medicinal Chemists and Drug Discovery leaders for an open, peer-led discussion on emerging therapeutic areas and modalities.
Featuring the Cambridge Chemistry Club, we are bringing together a curated group of biotech leaders and decision-makers to present and discuss emerging modalities, evolving drug discovery strategies, and real-world insights across diverse therapeutic areas.
• Cutting-edge platform technology leveraging advanced molecular dynamics to uncover protein metastates and reveal novel binding sites in difficult to target proteins.
• Combining RxPlorer™ with our in vitro capabilities, RxCelerate can deliver rapid hit identification and screening in 2 months.
Cambridge, UK and Cambridge, MA – 24/3/26 1pm GMT
We are pleased to announce the winners of the One Nucleus Awards 2026! The awards took place on 29 March in London.
The One Nucleus Award categories are structured to reflect that breadth of R&D, investment, service provision and enabling support across the stakeholders.
Many congratulations to the winners and finalists:
Best Therapeutic R&D Programme of the Year
⭐Winner: Resolution Therapeutics⭐
Finalists: Serenatis Bio, TRIMTECH Therapeutics
New parliamentary scrutiny of the UK’s innovation landscape has reinforced longstanding concerns about how investment in innovation is distributed across the country, with Pioneer Group, a specialist in technology infrastructure and venture building, urging swift action to address persistent barriers to research commercialisation.
Who we are:
Life, Reimagined
Constructive Bio is a VC-backed biotechnology startup based in Whittlesford, Cambridge. Our unique technology turns living cells into biofactories, creating sustainable new materials and therapeutics. With full control of the genetic sequence and code, we are exploring chemical space previously unreached by natural biology.
About Sygnature Discovery
At Sygnature Discovery, we create exceptional scientific outcomes. For our customers, who bring life-changing medicines to patients; and for our people, who help make this possible.
We’re 700+ scientists from over 50 countries, working as one across Europe and North America. With no competing internal programs, we offer total confidentiality and commitment.
Introduction to role:
Are you ready to lead API analytics that accelerate novel oncology medicines from concept to candidate selection and ultimately to reach patients? Do you thrive at the interface of LC-MS science, digital enablement, and cross-functional decision-making to unlock clearer, faster answers?
In this webinar, you will learn how to protect your organisation and clients against rising cyber threats, using AI and automation to enhance resilience while reducing operational costs.
Building and maintaining a Security Operations Centre (SOC) can cost upwards of £2 million. Managed Detection and Response (MDR) is rapidly becoming the default model for resilient, cost-effective cyber defence, delivering the same enterprise-grade security capabilities as a fully staffed SOC at a fraction of the cost.